← FDA DRUG APPROVALS

FDA ANDA · ANDA205050

TRAVOPROST OPHTHALMIC SOLUTION, 0.004%

Sponsor: MYLAN

APPLICATION
ANDA205050
TYPE
ANDA
ORIGINAL APPROVAL
2017-07-07
LATEST ACTION
2024-08-07
ROUTE
OPHTHALMIC
DOSAGE FORM
SOLUTION/DROPS
MARKETING STATUS
Prescription

Products

TRAVOPROSTPrescription
TRAVOPROST 0.004% · SOLUTION/DROPS · OPHTHALMIC

Approval history

2024-08-07Manufacturing (CMC) · Supplement 12 · unknownAP
2024-03-29Labeling · Supplement 4 · standardAP
2024-03-29Labeling · Supplement 3 · standardAP
2017-07-07UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →